GN Store Nord A/ S stock (DK0010272632): Hearing and health tech leader

GN Store Nord A/S develops advanced audio and hearing solutions for consumer and professional markets. The company reported strong growth in its hearing aid and audio segments in recent quarters, with key exposure to US healthcare and consumer electronics demand.

GN Store Nord A/S, a Danish medtech and audio specialist, continues to drive innovation in hearing aids and professional audio equipment. The company operates through two main divisions: GN Hearing and GN Audio, serving millions of users worldwide. Recent financials highlight resilience amid market shifts, with the stock listed on Nasdaq Copenhagen.

The stock traded at 140.50 DKK on 05/13/2026 on Nasdaq Copenhagen, according to Nasdaq Nordic as of 05/13/2026. Shares have shown stability, reflecting steady demand for its ReSound hearing aids and Jabra headsets.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: GN Store Nord A/S
• Sector/industry: Medtech / Audio equipment
• Headquarters/country: Denmark
• Core markets: US, Europe, Asia
• Key revenue drivers: Hearing aids, professional audio
• Home exchange/listing venue: Nasdaq Copenhagen (GN)
• Trading currency: DKK

GN Store Nord A/S: core business model

GN Store Nord A/S focuses on intelligent audio and hearing solutions. Its GN Hearing division leads in hearing aids under the ReSound brand, incorporating AI-driven features for personalized sound. GN Audio produces Jabra professional headsets for hybrid work and consumer earbuds. This dual-segment model diversifies revenue, with hearing care providing stability and audio capturing growth in unified communications.

The company invests heavily in R&D, spending about 10% of revenue on innovation as reported in its 2025 annual report published 03/07/2026 on GN IR as of 03/07/2026. This supports a pipeline of FDA-approved devices, key for US market penetration.

Main revenue and product drivers for GN Store Nord A/S

Hearing aids account for roughly 60% of revenue, driven by aging populations and OTC hearing aid adoption in the US following 2022 FDA rules. GN's ReSound ONE and Nexus platforms feature Bluetooth connectivity and telehealth integration. GN Audio contributes 40%, with Jabra Evolve series popular in US enterprise settings like call centers.

In Q1 2026 results published 05/07/2026, GN reported revenue of 4.2 billion DKK, up 8% year-over-year, per GN IR as of 05/07/2026. US sales grew 12%, underscoring exposure to American healthcare spending.

Industry trends and competitive position

The global hearing aid market is projected to reach $10 billion by 2028, per Statista data published 01/15/2026. GN competes with Sonova and Demant but differentiates via software ecosystems. In professional audio, Jabra holds strong UC market share against Logitech and Poly, bolstered by Microsoft Teams certification.

GN's US relevance stems from its ReSound distribution through 5,000+ audiologists and partnerships with US health insurers, aligning with Medicare expansions.

Why GN Store Nord A/S matters for US investors

GN Store Nord A/S offers US investors access to Europe's medtech growth via its Copenhagen listing, with ADRs available OTC. The company's 25% US revenue share ties it to American demographics—78 million baby boomers—and telehealth trends post-COVID. Its products support remote work, a staple in US offices.

Exchange rate dynamics between DKK and USD add a forex layer, but stable dividends enhance appeal for income-focused portfolios.

Conclusion

GN Store Nord A/S maintains a solid position in hearing health and audio communications, with recent results showing balanced growth across segments. Exposure to US markets provides tailwinds from demographic and tech trends. Investors track upcoming Q2 earnings and product launches for further insights into performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.